ESP | ENG

International Registry iBIOGEAS (31-07-07)

Data on each Biologic Agent

  1. Infliximab (516 patients)
  2. Rituximab (286 patients)
  3. Etanercept (258 patients)
  4. Anakinra (13 patients)
  5. Adalimumab (8 patients)
  6. Epratuzumab (14 patients)
  7. Efalizumab (13 patients)
  8. Alemtuzumab (1 patients)
  9. Ocrelizumab (1 patients)